Long non-coding RNA CASC15 promotes melanoma progression by epigenetically regulating PDCD4

Yakun Yin¹†, Bin Zhao²†, Dongqin Li¹ and Guangwen Yin¹*

Abstract

Background: Long non-coding RNAs (lncRNAs) have been identified as critical regulators in a variety of cancer types. Cancer susceptibility candidate 15 (CASC15), a lncRNA located at chromosome 6p22.3, has been discovered to participate in melanoma progression and phenotype switching. Nevertheless, the roles and molecular mechanisms of CASC15 in melanoma are far from being understood.

Results: We found that CASC15 expression was up-regulated in melanoma tissues and associated with advanced pathological stages. Function experiments displayed that CASC15 knockdown hindered proliferation, facilitated apoptosis and suppressed invasion, while CASC15 overexpression facilitated proliferation and invasion in melanoma cells. Further mechanistic analysis showed that CASC15 epigenetically silenced the expression of programmed cell death 4 (PDCD4) by recruiting EZH2 and increasing H3K27me3 level at the promoter region of PDCD4. Additionally, PDCD4 overexpression inhibited proliferation, enhanced apoptosis and decreased invasion of melanoma cells. Moreover, CASC15-knockdown-induced anti-cancer effects were abated by PDCD4 down-regulation. Furthermore, depletion of CASC15 blocked tumor growth of melanoma by up-regulating PDCD4 in vivo.

Conclusions: CASC15 acts as an oncogene by negatively regulating PDCD4 expression via recruiting EZH2 and subsequently increasing H3K27me3 level. Together, our study indicates that CASC15/EZH2/PDCD4 may serve as a promising therapeutic target for melanoma intervention.

Keywords: Melanoma, LncRNA, CASC15, PDCD4, EZH2

Background

Melanoma, one of the most aggressive cutaneous carcinoma, arises from melanocytes that produce pigment melanin [1]. In 2017, it is estimated that there exist approximately 87,110 new cases of melanoma and 9730 deaths from melanoma in the United States [2]. Though the treatment options for melanoma have progressed tremendously over the past decade [3], patients in distant stage still display an unfavourable prognosis due to high metastatic potential, with a 5-year survival rate of only 17% [4]. Thus, exploring the possible molecular mechanisms of melanoma initiation and progression is imperative for developing innovative therapeutic strategies of melanoma.

Long non-coding RNAs (lncRNAs) are defined as a type of transcripts with more than 200 nucleotides in length and little protein-coding potential. LncRNAs have been shown to control gene expression via multiple mechanisms, including genetic imprinting, chromatin remodeling, transcriptional regulation, post-transcriptional regulation, and translational regulation [5]. A variety of lncRNAs have been demonstrated to affect cancer phenotype through modulating proliferation, cell cycle, apoptosis, migration, invasion and angiogenesis in different malignant tumors [6]. Enhancer of zeste homolog 2 (EZH2), a key catalytic component of the polycomb repressive complex 2 (PRC2), acts as a histone methyltransferase that alter histone H3 lysine 27 trimethylation...
(H3K27me3) and modulate gene expression [7]. LncRNAs have been reported to be able to interact with EZH2, thus affecting the genes associated with a serial of cellular processes in kinds of cancers [8]. For instance, LncRNA PVT1 recruited EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and inhibited LATS2 transcription, thereby promoting proliferation and decreased apoptosis in non-small cell lung cancer cells [9]. LncRNA CRNDE contributed to colorectal cancer progression via epigenetically repressing DUSP5 and CDKN1A transcription via binding to EZH2 [10]. LncRNA PCAT-1 promoted proliferation and migration of osteosarcoma cells possibly through binding with EZH2 to transcriptionally suppress p21 expression [11].

Cancer susceptibility candidate 15 (CASC15), also annotated as LINCO0340, is located on chromosome 6p22.3 and initially identified in silico as a highly active LncRNA [12]. Russell et al. [13] reported that CASC15 depletion facilitated proliferation and invasive capabilities in neuroblastoma, elucidating its antitumor effect in neuroblastoma. Interestingly, CASC15 expression was up-regulated and acted as a carcinogene in hepatocellular carcinoma [14] and gastric cancer [15]. Moreover, a recent document revealed that CASC15 was associated with melanoma development and disease recurrence, and knockdown of CASC15 induced a cell phenotype switching between proliferative and invasive states [16]. However, the precise functional roles and potential molecular basis of CASC15 in melanoma are far from being elucidated.

In this study, study, we found that CASC15 expression was up-regulated in melanoma tissues compared with adjacent normal tissues. Furthermore, CASC15 knockdown repressed proliferation and invasion, and enhanced apoptosis of melanoma cells partly by epigenetically regulating PDCD4 expression via binding to EZH2.

**Methods**

**Clinical specimen**

A cohort of 42 tumor tissues and adjacent normal tissues were collected from melanoma patients at the First Affiliated Hospital of Zhengzhou University between March 2014 and May 2016. No patients had received radiotherapy or chemotherapy prior to surgery resection. All tissues were maintained at −80 °C until RNA extraction. The histological diagnosis of melanoma was confirmed in accordance with the World Health Organization (WHO) criteria. This study was performed with approval of the Ethic Committee of the First Affiliated Hospital of Zhengzhou University following the Declaration of Helsinki Principles. All patients signed the written informed consents before enrolling in this study.

**Cell culture**

Melanoma cell lines (A375, SK-MEL-2, M21, MEL-RM, B16, and SK-MEL-1) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All melanoma cell lines were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Invitrogen) and 100 U/ml of penicillin/streptomycin (Invitrogen). Normal human epidermal melanocytes (HEMa-LP) were obtained from Invitrogen and maintained in Medium 254 (Cascade Biologics, Portland, OR, USA) supplemented with human melanocyte growth supplement (Cascade Biologics). All culture was performed in a humidified incubator with 5% CO₂ atmosphere at 37 °C.

**Oligonucleotides, plasmid constructs and transfection**

Small interference RNAs (siRNAs) specifically targeting CASC15 (si-CASC15#1, si-CASC15#2), siRNA specifically against EZH2 (si-EZH2), siRNA specifically targeting PDCD4 (si-PDCD4), and scrambled oligonucleotides used as negative control (si-con) were chemically synthesized by GenePharma (Shanghai, China). To overexpress CASC15 or programmed cell death 4 (PDCD4), the full length cDNA sequences of CASC15 or PDCD4 were amplified and inserted into pcDNA3.1 vector (Invitrogen), named as pcDNA-CASC15 and pcDNA-PDCD4. Lipofectamine 2000 (Invitrogen) was used to transfect oligonucleotides and constructs into melanoma cells according to the manufacturer’s instruction.

**RNA extraction and qRT-PCR**

Total RNA was isolated from melanoma tissues and cells using TRIzol reagent (Invitrogen) according to the manufacturer's specification. The first-strand cDNA was synthesized from 1 μg of total RNA using PrimeScript™ II 1st Strand cDNA Synthesis Kit (Takara, Dalian, China). qRT-PCR reaction was conducted with ABI power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on an ABI Prism 7900 Sequence Detection System (Applied Biosystems). The relative expressions of CASC15 and PDCD4 mRNA were measured using the 2−ΔΔCt method with GAPDH as an internal control.

**Cell proliferation analysis**

The cell proliferation ability was assessed by Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) according to the manufacture’s specification. Briefly, transfected A375 and M21 cells were inoculated into 96-well plates at a density of 2 × 10^4 cells/well. At the indicated time points (24, 48, 72, and 96 h), 10 μl of CCK-8 solution was added into each well. After incubation for another 2 h at 37 °C, the absorbance was
determined by a microplate reader (Molecular Devices, Sunnyvale, CA, UAS) at a wavelength of 450 nm.

**Cell cycle analysis**

After 48 h of incubation, A375 and M21 cells were collected, washed with PBS, fixed in 70% ethanol, and then stained with 50 μg/ml propidium iodide (PI) containing 40 μg/ml RNase. Following incubation at 37 °C for 30 min in the dark, a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) was used to analyze the percentages of cells in G0/G1, S, and G2/M phases.

**Cell apoptosis analysis**

After 48 h of incubation, A375 and M21 cells were harvested, washed with PBS, and stained with fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide in the dark at room temperature using FITC Annexin V Apoptosis Detection Kit (BD Biosciences). Then, the apoptotic rate was measured by a FACSCalibur flow cytometer (BD Biosciences).

**Cell invasion analysis**

Cell invasion assays were carried out using a transwell chamber (Corning Incorporated, Corning, NY, USA) precoated with Matrigel (BD Biosciences, San Diego, CA, USA). Totally, A375 and M21 cells (1 × 10^5) suspended in 200 μl serum-free medium with 1 μg/ml Mitomycin C were added into the upper chamber, while 600 μl complete medium with 10% FBS was added into the lower chamber. After incubation for 24 h, cells on the upper surface of the membrane were removed with a cotton swab, and cells on the lower surface were fixed with methanol, stained with crystal violet, and counted in five random fields under an inverted microscope.

**Western blot analysis**

The total protein was extracted from melanoma tissues and cells using RIPA buffer (KeyGEN Biotech, Nanjing, China). A Pierce BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA) was applied to determine the protein concentrations. Equal amount of protein (30 μg) was separated by 10% SDS-PAGE gel and transferred to PVDF membranes (Millipore, Billerica, MA, USA). Then, the membranes were blocked with 5% skimmed milk and incubated overnight with primary antibodies against PDCD4 (Cell Signaling Technology, Beverly, MA, USA), EZH2 (Cell Signaling Technology) and β-actin (Cell Signaling Technology), followed by probed with horseradish peroxidase-labeled secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, UAS). β-actin was used as an endogenous control. ECL chromogenic substrate (Thermo Fisher Scientific) was used to detect the protein bands.

**Subcellular fractionation location**

The separation of nuclear and cytoplasmic RNA was performed using Cytoplasmic & Nuclear RNA Purification Kit (Norgen, Belmont, CA, USA) according to manufacturer's guidance.

**Dual-luciferase reporter assay**

The PDCD4 promoter reporter vector was purchased from Genechem (Shanghai, China). Melanoma cells were co-transfected with the reporter promoter and si-CASC15 or si-con. After 48 h, the luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).

**RNA immunoprecipitation (RIP) assays**

Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore) was applied to perform RIP experiments on the basis of the manufacturer's manual. Antibody for EZH2 RIP assay was purchased from Cell Signaling Technology. IgG antibody (Cell Signaling Technology) was used as a negative control. The co-precipitated RNAs were purified and analyzed by qRT-PCR analysis.

**RNA–protein pull down assays**

CASC15 and antisense-CASC15 was in vitro transcribed with TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific), and then labeled with biotin using Pierce RNA 3′ Desthiobiotinylation Kit (Thermo Fisher Scientific). A Pierce Magnetic RNA–Protein Pull down Kit (Thermo Fisher Scientific) was applied to perform RNA–protein pull-down experiments. Briefly, biotinylated transcripts were mixed with melanoma cell lysates, followed by incubation with streptavidin agarose beads (Invitrogen) for 1 h at 25 °C. Finally, the retrieved protein was detected by western blot.

**Chromatin immunoprecipitation (ChIP) assays**

ChIP assays were conducted using the EZ ChIP™ kit (EMD Millipore) according to the manufacturer’s instruction. Briefly, melanoma cells were fixed with 1% formaldehyde to obtain protein-DNA crosslinks. Then cells were washed, lysed and sonicated to acquire chromatin fragments of 200–1000 bp. Subsequently, the chromatin was immunoprecipitated with antibodies against EZH2 (Abcam), H3K27me3 (Millipore) or IgG (Millipore), and then further incubated with magnetic beads. Precipitated chromatin DNA was recovered and analyzed by qRT-PCR. The primer sequences for PDCD4 promoter region amplification are listed as follows: PDCD4, 5′-GGATAAGTTGATTTATTTGGAGT-3′ (sense) and 5′-TTATTTTTATTTCTCTACCCAT-3′ (anti-sense). ChIP data is presented as a percentage relative to input DNA.
Animal experiments
Male BALB/c athymic nude mice (5 weeks old) were purchased from the Shanghai Experimental Animal Center of Chinese Academy of Sciences (Shanghai, China) and maintained under specific pathogen-free conditions. A375 cells ($1 \times 10^7$) stably transfected with sh-con or sh-PVT1 were subcutaneously injected into the tail veins of mice. Tumor sizes were measured every 4 days. At 28 days after injection, the mice were killed and tumor weights were detected. qRT-qPCR was used to evaluate CASC15 expression, and western blot was employed to determine the levels of Ki-67 and PDCD4 in resected tumor masses.

Statistical analysis
All data were shown as mean±standard deviation (mean±SD). The difference between groups was analyzed using one-way ANOVA or Student’s t test by SPSS 17.0 software (IBM, Chicago, IL, USA). The correlation between CASC15 and PDCD4 mRNA expression was evaluated by Pearson correlation analyses. $P<0.05$ was considered as statistically significant.

Results
CASC15 expression was up-regulated in melanoma tissues and associated with melanoma progression
Firstly, we analyzed CASC15 expression in 461 melanoma tissue samples and 558 normal tissue samples using the bioinformatics tool GEPIA (http://gepia.cancer-pku.cn/detail.php?gene=), and the data showed that CASC15 expression was increased in melanoma tissue (Fig. 1a). Moreover, CASC15 expression was enhanced with the development of melanoma stage (Fig. 1b). Then, we evaluated the expression of CASC15 in 42 pairs of melanoma tissue and adjacent non-cancerous tissues. The results showed that CASC15 expression was up-regulated in melanoma cells (A375, SK-MEL-2, M21, MEL-RM, B16 and SK-MEL-1) and normal human epidermal melanocytes (HEMa-LP). Results are represented as mean±SD of three independent experiments. *$P<0.05$, **$P<0.01$, ***$P<0.001$
revealed that CASC15 expression was obviously higher in melanoma tissues than that in corresponding normal tissues (Fig. 1c). Also, CASC15 expression was dramatically up-regulated in higher stage patients compared with lower stage patients (Fig. 1d). Additionally, CASC15 expression was increased in metastatic melanoma tissues in comparison with that in primary melanoma tissues (Fig. 1e). The correlation between CASC15 expression and clinicopathological features in melanoma patients was displayed in Table 1. The data demonstrated that CASC15 expression was associated with TNM stage (P = 0.013), distal metastasis (P = 0.018), and lymphatic metastasis (P = 0.006), but was not related to other clinical characteristics, such as age and gender in melanoma. Furthermore, we explored the level of CASC15 in several melanoma cells (A375, SK-MEL-2, M21, MEL-RM, B16 and SK-MEL-1) and normal human epidermal melanocytes (HEMa-LP). The results presented that CASC15 was much more abundant in melanoma cells than that in HEMa-LP cells (Fig. 1f). These results indicated that up-regulated CASC15 might participate in melanoma progression.

**Knockdown of CASC15 repressed proliferation, induced apoptosis and decreased invasion in melanoma cells**

To investigate the biological effects of CASC15 on melanoma development, we lowered endogenous CASC15 expression in A375 and M21 cells by two specific siRNAs targeting CASC15 (si-CASC15 #1 and si-CASC15 #2) (Fig. 2a, b). CCK-8 assays disclosed that silenced CASC15 significantly suppressed the proliferation ability of A375 and M21 cells (Fig. 2c, d). Cell cycle analysis uncovered that knockdown of CASC15 resulted in an evident cell cycle arrest at G0–G1 phase in A375 and M21 cells (Fig. 2e, f). Also, flow cytometry assay discovered that the apoptotic rate was remarkably enhanced in A375 and M21 cells following the down-regulation of CASC15 (Fig. 2g, h). Additionally, transwell invasion analysis manifested that depletion of CASC15 greatly alleviated the invasive capability of A375 and M21 cells (Fig. 2i, j). Together, knockdown of PVT1 inhibited proliferation, promoted apoptosis and impaired invasion in melanoma cells.

**Overexpression of CASC15 induced proliferation and invasion in melanoma cells**

Simultaneously, gain-of-function experiment was performed in melanoma cells by transfection with pcDNA-CASC15. As we might expect, CASC15 expression was successfully increased in both A375 and M21 cells following introduction with pcDNA-CASC15 (Fig. 3a). Further function assays disclosed that enforced expression of CASC15 greatly promoted proliferation (Fig. 3b), induced cell cycle progression (Fig. 3c) and enhanced invasion (Fig. 3e) in A375 and M21 cells. Moreover, no significant change was observed in apoptotic rate of melanoma cells following CASC15 overexpression (Fig. 3d). Collectively, enforced expression of CASC15 promoted melanoma progression.

**CASC15 suppressed PDCD4 expression by interacting with EZH2**

It has been reported that approximately 20% of human lncRNAs recruit PRC2 to specific genome sites to silence gene expression [17]. CASC15 was previously revealed to be involved in the tumorigenesis of gastric cancer via interacting with EZH2 and WDR5 in nucleus [15]. PDCD4, a tumor suppressor, was previously proved to be down-regulated by PRC2 complex via increasing the level of H3K27me3 at its promoter in glioma [18]. Thus, we wondered whether CASC15 could regulate PDCD4 expression through EZH2 in melanoma. To prove this hypothesis, we firstly analyzed the effects of CASC15 knockdown on PDCD4 expression in melanoma cells. To prove this hypothesis, we firstly analyzed the effects of CASC15 knockdown on PDCD4 expression in melanoma cells, and the results stated that PDCD4 expression was evidently enhanced in si-CASC15 #2-transfected A375 and M21 cells (Fig. 4a). Then, subcellular fractionation location assays displayed that CASC15 was distributed both in nucleus and cytoplasm of A375 and M21 cells (Fig. 4b, c), implying that CASC15 may exert regulatory function at transcriptional and post-transcriptional levels. Subsequently, we probed the interaction possibility of CASC15

---

**Table 1 Correlation between CASC15 expression and clinicopathological characteristics in melanoma patients**

| Characteristics     | CASC15 expression | P value |
|---------------------|-------------------|---------|
|                     | Low | High |     |
| Age                 |     |      | 0.053 |
| ≤ 50                | 11  | 13   |     |
| > 50                | 7   | 11   |     |
| Gender              |     |      | 0.789 |
| Male                | 9   | 13   |     |
| Female              | 9   | 11   |     |
| TNM stage           |     |      | 0.013 |
| I–II                | 13  | 8    |     |
| III                 | 5   | 16   |     |
| Distal metastasis   |     |      | 0.018 |
| M0                  | 11  | 6    |     |
| M1                  | 7   | 18   |     |
| Lymphatic metastasis|     |      | 0.006 |
| N0                  | 13  | 7    |     |
| N1–N3               | 5   | 17   |     |

* P < 0.05 was considered statistically significant
Fig. 2 Knockdown of CASC15 suppresses proliferation, enhanced apoptosis and decreased invasion in melanoma cells. A375 and M21 cells were transfected with si-con, si-CASC15 #1, or si-CASC15 #2. a, b qRT-PCR analysis was used to determine the relative expression of CASC15 in transfected A375 and M21 cells. c, d CCK-8 analysis was performed to measure the proliferation ability in transfected A375 and M21 cells. e, f Flow cytometry analysis was applied to detect cell cycle distribution in transfected A375 and M21 cells. The bar chart represents the percentage of cells in G1/G0, S, and G2/M phases. g, h The apoptotic rate of transfected A375 and M21 cells was analyzed by flow cytometry. i, j Transwell invasion assay was conducted to assess the invasive capability of transfected A375 and M21 cells. Results are represented as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01
and EZH2 using RNA–protein interaction prediction website (http://pridb.gdcb.iastate.edu/RPISeq/). The data showed that CASC15–EZH2 interaction score was 0.65 using RF classifier, and 0.98 using SVM classifier (Fig. 4d). Moreover, down-regulation of EZH2 led to an obvious increase of PDCD4 expression when compared to negative control group in A375 and M21 cells (Fig. 4e), suggesting that EZH2 could modulate PDCD4 expression. Also, luciferase reporter assays revealed that depletion of CASC15 increased the activity of PDCD4 promoter in both A375 and M21 cells, indicating that CASC15 could regulate PDCD4 expression at the transcriptional level (Fig. 4f).

Next, to verify whether CASC15 could directly bind to EZH2, RIP and RNA–protein pull down assays were conducted in A375 and M21 cells. RIP assays showed that CASC15 level was greatly enriched by EZH2 antibody (Fig. 4g, h). RNA–protein pull down experiments

![Fig. 3](image)

Fig. 3  CASC15 overexpression facilitates proliferation and invasion in melanoma cells. A375 and M21 cells were transfected with pcDNA empty vector or pcDNA-CASC15, followed by the evaluation of CASC15 expression (a), cell proliferation (b), cell cycle distribution (c), apoptosis (d) and invasion (e).

![Fig. 4](image)

Fig. 4  CASC15 epigenetically silences PDCD4 expression by binding to EZH2. a Western blot assay was carried out to evaluate the protein level of PDCD4 in A375 and M21 cells transfected with si-con or si-CASC15 #2. b, c qRT-PCR assay was used to measure CASC15 expression in cytoplasm and nucleus of A375 and M21 cells. GAPDH was used as a cytoplasm marker and U6 was used as a nucleus marker. d The probability of interaction of CASC15 and EZH2 was predicted by RNA–protein interaction prediction website (http://pridb.gdcb.iastate.edu/RPISeq/). Predictions with probabilities > 0.5 were considered positive. RPISeq predictions are based on Random Forest (RF) or Support Vector Machine (SVM). e Western blot assay of PDCD4 protein expression in A375 and M21 cells after transfection with si-con or si-EZH2. f Luciferase reporter assay was performed in both A375 and M21 cells after co-transfection with PDCD4 promoter reporter and si-con or si-CASC15. g, h RIP experiments were conducted in A375 and M21 cells, followed by qRT-PCR analysis of CASC15 in the coprecipitated RNA. The fold enrichment of CASC15 in EZH2 RIP is relative to its matched IgG control. i, j In vitro transcribed biotin-labeled CASC15 and anti-CASC15 were incubated with A375 and M21 cell lysates, and the extracted protein was analyzed by western blot using an antibody against EZH2. A nonspecific protein (β-actin) is shown as the control. k, l ChIP of EZH2 occupancy and H3K27me3 binding in the PDCD4 promoter in A375 and M21 cells after transfection with si-con or si-CASC15 #2. Enrichment was quantified relative to input control. Antibody against IgG was used as a negative control. m PDCD4 mRNA expression in melanoma tissues (n = 461) and normal tissues (n = 558) from GEPIA database (http://gepia.cancer-pku.cn/detail.php?gene=PDPCD4). n Relative expression levels of PDCD4 mRNA in melanoma tissues (n = 42) and adjacent normal tissues (n = 42). o Spearman correlation analysis of CASC9 and PDCD4 expression in 42 melanoma tissues. Results are represented as mean ± SD of three independent experiments. **P < 0.01
also demonstrated that labeled CASC15 could pull down EZH2 rather than antisense CASC15 from the nuclear extract fraction of A375 and M21 cells (Fig. 4i, j). Together, these results indicated that CASC15 could interact with EZH2 in melanoma cells. To further address whether CASC15 engage in transcriptional repression through the enrichment of EZH2 to PDCD4 promoter, we performed ChIP analysis in A375 and M21 cells. The results declared that EZH2 could bind to PDCD4 promoter region and induce H3K27 trimethylation, while CASC15 knockdown decreased EZH2 binding and H3K27ME3 occupancy of PDCD4 promoter (Fig. 4k, l).

Additionally, as presented in Fig. 3m, GEPIA database (http://gepia.cancer-pku.cn/detail.php?gene=&click tag=boxplot) analysis showed that PDCD4 expression was significantly down-regulated in melanoma tissue
samples (n = 461) compared with normal tissue samples (n = 558). As expected, we found that PDCD4 expression was lower in 42 cases of melanoma tissue samples than that in normal counterparts (Fig. 4n). Moreover, a negative correlation was observed between CASC15 and PDCD4 expression in melanoma patients (Fig. 4o). All these data supported the conclusion that CASC15 epigenetically inhibited PDCD4 expression by recruiting EZH2 to its promoter region and increasing the H2K27me3 level of its promoter in melanoma.

PDCD4 overexpression hindered proliferation, enhanced apoptosis and suppressed invasion in melanoma cells

To investigate the functions of PDCD4 in melanoma progression, we constructed PDCD4-overexpression plasmid (pcDNA-FOXF1) and transfected it into A375 and M21 cells. qRT-PCR analysis confirmed that PDCD4 expression was prominently enhanced at mRNA and protein level in A375 and M21 cells after transfection with pcDNA-PDCD4 (Fig. 5a, b). CCK-8 experiments illustrated that enforced expression of PDCD4 resulted in an apparent decrease of A375 and M21 cell proliferation (Fig. 5c). Flow cytometry analysis showed a G0–G1 cell cycle arrest and an increased apoptotic rate in A375 and M21 cells following PDCD4 up-regulation (Fig. 5d, e). Transwell invasion assay found that the invasive ability of A375 and M21 cells was substantially abated after introduction with pcDNA-PDCD4 (Fig. 4f). In summary, overexpression of CASC15 blocked proliferation, promoted apoptosis and attenuated invasion in melanoma cells.

The tumor-suppressive effect mediated by CASC15 knockdown was weakened following depletion of PDCD4

To further explore whether the effect of CASC15 on melanoma progression was mediated by PDCD4, we performed the restoration experiment in A375 cells by co-transfection with si-CASC15 and si-PDCD4. As presented in Fig. 6a, si-CASC15-induced increase of PDCD4 expression was attenuated by down-regulating PDCD4. Moreover, the anti-proliferation (Fig. 6b, c), pro-apoptosis (Fig. 6d) and anti-invasion (Fig. 6e) effects elicited by CASC15 knockdown were greatly reversed following PDCD4 depletion. In all, CASC15 promoted melanoma progression through regulating PDCD4.

Depletion of CASC15 suppressed melanoma tumorigenesis in vivo

To further determine the roles of CASC15 in melanoma tumorigenesis in vivo, sh-CASC15- or sh-con-transfected A375 cells were subcutaneously inoculated into the nude mice. The data displayed that CASC15 knockdown significantly decreased the tumor volumes (Fig. 7a) and lowered the tumor weights (Fig. 7b, c). Moreover, the expression of Ki-67 was strikingly reduced in tumors developed from sh-CASC15-transfected A375 cells compared with sh-con group (Fig. 7d). Additionally, CASC15 expression was declined (Fig. 7e) and PDCD4 protein level was increased (Fig. 7f) in tumor masses of sh-CASC15 group when compared to that of control group. All these data demonstrated that knockdown of CASC15 inhibited melanoma cell proliferation in vivo possibly by regulating PDCD4.

Discussion

A growing body of evidence highlights that lncRNAs regulate cell proliferation, differentiation, migration and invasion in the occurrence and development of diverse malignant tumors, including melanoma [19, 20]. CASC15 was previously discovered to affect cell phenotype switching between proliferative and invasive states in melanoma [16]. Nevertheless, further investigations on the biological significance and underlying mechanism of CASC15 in melanoma are required.

Firstly, we found that CASC15 expression was increased in melanoma tissues and cells. Moreover, higher CASC15 level was associated with advanced TNM stage and metastasis. Subsequent loss- and gain-of-function experiments showed that CASC15 knockdown inhibited proliferation, facilitated apoptosis and decreased invasion of melanoma cells, while CASC15 overexpression displayed the opposite effects. Consistent with our findings, Yao et al. delineated that CASC15 was highly expressed in gastric cancer tissues and cells, and down-regulation of CASC15 impaired the proliferation capability of gastric cancer cells [21]. He et al. reported that CASC15 was overexpressed in hepatocellular carcinoma tissues and cells, and depletion of CASC15 repressed proliferation, promoted apoptosis, and lowered invasion of hepatocellular carcinoma cells [14]. Conversely, CASC15 was validated as a tumor suppressor in neuroblastoma [13] and acute leukemia [22].

It has been well known that lncRNAs may regulate downstream effectors through EZH2-driven H3K27 promoter methylation in multiple cancers, including melanoma [23, 24]. For example, IncRNA FALEC contributed to melanoma progression via epigenetically silencing p21 expression via recruiting EZH2 to its promoter [25]. PDCD4, a tumor suppressor, was recently demonstrated to be negatively regulated by CASC9, via recruiting EZH2 and subsequently changing H3K27me3 level in esophageal squamous cell carcinoma [26]. Thus, we further analyzed whether CASC15 could modulate PDCD4 expression through recruiting EZH2.
blot analysis showed that knockdown of CASC15 or EZH2 both induced the expression of PDCD4 in melanoma cells. Moreover, CASC15 was verified to be distributed in nucleus and cytoplasm, implying its potential transcriptional regulation function. Luciferase reporter analysis verified that CASC15 could regulate PDCD4 expression at the transcriptional level. Subsequent RIP and RNA–protein pull down assays further certified the binding between CASC15 and EZH2. Further ChIP assays disclosed that EZH2 could directly bind to the promoter of PDCD4 in melanoma cells, and depletion of CASC15 lowered the binding ability of EZH2 to the promoter region of PDCD4 and reduced H3K27 trimethylation. Taken together, CASC15 inhibited PDCD4 expression partially by recruiting EZH2 to its promoter region in melanoma. Concordant with our results,
CASC15 was found to affect the tumorigenesis of gastric cancer by regulating CDKN1A via interaction with EZH2 and WDR5 in nucleus, meanwhile, CASC15 participated in gastric cancer progression by modulating ZEB1 expression through sponging miR-33a-5p in cytoplasm [15]. However, in melanoma, the regulatory mechanisms of CASC15 in cytoplasm are required to be further discussed.

PDCD4 has been identified as a tumor suppressor gene and potential anticancer target for several years [27, 28]. Accumulating evidence has elucidated that PDCD4 could exert antitumor activity in a variety of cancer types, such as bladder cancer [29], colon carcinoma [30] and oropharyngeal cancer [31], via different regulatory pathways. In this study, PDCD4 expression was found to be down-regulated and negatively correlated with CASC15 expression in melanoma tumor tissues. Gain-of-function assay confirmed that overexpression of PDCD4 blocked proliferation, induced apoptosis and repressed invasion of melanoma cells. In agreement with our data, PDCD4 was demonstrated to be decreased in melanoma tumor tissues, and inhibited melanoma cell proliferation, migration and invasion [32, 33]. Furthermore, restoration experiment

![Image](image_url)
uncovered that PDCD4 silencing greatly reversed the anti-cancer function induced by CASC15 knockdown. Finally, transplantation tumor experiments revealed that knockdown of CASC15 inhibited tumor growth in vivo possibly via up-regulating PDCD4 expression.

Conclusions
In conclusion, our study demonstrated that CASC15 contributed to melanoma progression partially by EZH2-medicated silence of PDCD4 expression, illuminating the promising prospect of CASC15 as a potential target and therapeutic application for melanoma patients. However, the other possible regulatory mechanisms of CASCA15 in melanoma cell functions remain require further investigation.

Abbreviations
lncRNAs: long non-coding RNAs; EZH2: enhancer of zeste homolog 2; PRC2: polycomb repressive complex 2; H3K27me3: histone H3 lysine 27 trimethylation; LATS2: large tumor suppressor kinase 2; CASC15: cancer susceptibility candidate 15; HEMa-LP: human epidermal melanocytes; siRNAs: small interference RNAs; RIP: RNA immunoprecipitation; ChIP: chromatin immunoprecipitation.

Authors’ contributions
YKY and GWY designed the study. YKY and BZ conducted the experiments, analyzed the data, and prepared the manuscript. DQL and GWY edited and the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Dermatology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian She East Road, Zhengzhou 450052, China. 2 Department of Dermatology, The Third People’s Hospital of Henan Province, No 198 Fu Niu Road, Zhengzhou 450006, China.

Acknowledgements
We want to thank all participants involved in this study.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was approved by the Ethic Committee of the First Affiliated Hospital of Zhengzhou University following the Declaration of Helsinki Principles. Written informed consents were obtained from each participant involved in this study.

Funding
None.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 4 May 2018  Accepted: 7 July 2018
Published online: 13 July 2018

References
1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851–7.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
3. Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU. Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol. 2018;19:303–17.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2015;66:7–30.
5. Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long non-coding RNAs on gene expression in cancers. Cancer Genet. 2017;216–217:105–10.
6. Camacho CV, Choudhari R, Gadad SS. Long noncoding RNAs and cancer, an overview. Steroids. 2018;133:93–5.
7. Cao R, Wang L, Wang H, Xia L, Erdjumentbromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298:1039–43.
8. Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer. 2013;133:267–74.
9. Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, et al. Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther. 2016;15:1082–94.
10. Ding J, Li J, Wang H, Tian Y, Xie M, He X, et al. Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5/Cdkn1a expression. Cell Death Dis. 2017;8:e2997.
11. Huang J, Deng G, Liu T, Chen W, Zhou Y. Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels. Biochem Biophys Res Commun. 2017;495:2622–9.
12. Gusliman G, Qin S, El-Gewely MR, Siegel AF, Roach JC, Hood L, et al. A third approach to gene prediction suggests thousands of additional human transcribed regions: PLoS Comput Biol. 2006;2:e18.
13. Russell MR, Penikis A, Oldridge DA, Alvarez-Zuniga SN, McDaniel L, Diamond M, et al. CASC15-S is a tumor suppressor IncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer Res. 2015;75:3155–66.
14. He T, Zhang L, Kong Y, Huang Y, Zhang Y, Zhou D, et al. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. Int J Oncol. 2017;51:1722–30.
15. Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng W, et al. Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. Mol Oncol. 2018;12:799–813.
16. Lessard L, Liu M, Marzea DM, Wang H, Chong K, Kawas N, et al. The CASC15 long intergenic noncoding RNA locus is involved in melanoma progression and phenotype switching. J Invest Dermatol. 2015;135:2464–74.
17. Khalil AM, Guttmann M, Huarte M, Garber M, Raj A, Morales DR, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009;106:11667–72.
18. Chen Y, Bian Y, Zhao S, Kong F, Li X. Suppression of PDCD4 mediated by the long non-coding RNA HOTAIR inhibits the proliferation and invasion of glioma cells. Oncol Lett. 2016;12:5170–6.
19. Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dingere ME, Liu PY, et al. The regulatory role of long noncoding RNAs in cancer. Cancer Lett. 2017;391:12–9.
20. Yu X, Zheng H, Tse G, Chan MT, Wu WK. Long non-coding RNAs in melanoma. Cell Prolif. 2018. https://doi.org/10.1111/cpr.12457.
21. Yao XM, Tang JH, Zhu H, Jing Y. High expression of IncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:5661–7.
22. Fernando TR, Contreras JR, Zapimpi M, Rodriguez-Malave NJ, Alberti MO, Anguiano J, et al. The IncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Mol Cancer. 2017;16:126.
23. Sarkar D, Leung EY, Baguley BC, Finlay GJ, Aksitamam ME. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10:103–21.
24. Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, et al. EZH2 in cancer progression and potential application in cancer therapy: a friend or foe? Int J Mol Sci. 2017;18:E1172.
25. Ni N, Song H, Wang X, Xu X, Jiang Y, Sun J. Up-regulation of long noncoding RNA FALEC predicts poor prognosis and promotes melanoma cell proliferation through epigenetically silencing p21. Biomed Pharmacother. 2017;96:1371–9.
26. Wu Y, Hu L, Liang Y, Li J, Wang K, Chen X, et al. Up-regulation of IncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer. 2017;16:150.
27. Lankat-Buttgerit B, Goke R. The tumor suppressor Pdcod4: recent advances in the elucidation of function and regulation. Bio Cell. 2009;101:309–17.
28. Li JZ, Wei G, Ho WK, Wen BL, Wei WI, Chan YW, et al. The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis. Chin J Cancer. 2016;35:95.
29. Liu J, Zhai R, Zhao J, Kong F, Wang J, Jiang W, et al. Programmed cell death 4 overexpression enhances sensitivity to cisplatin via the JNK/c-Jun signaling pathway in bladder cancer. Int J Oncol. 2018. https://doi.org/10.3892/ijo.2018.4303.
30. Wang Q, Zhu J, Wang YW, Dai Y, Wang YL, Wang C, et al. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma. Oncogene. 2017;36:2225–34.
31. Zhang X, Gao H, Wu J, Che X, Liang M, Bai J, et al. Up-regulation of long non-coding RNA CASC9 regulates the proliferation of glioma cells. Oncol Lett. 2016;12:5170–6.
32. Xiao Q, Xue L, Gao Y, Shi M, Liang J, Sun J, et al. Long non-coding RNA CASC15 regulates SOX4 expression in the ERK/NF-κB signaling pathway to affect the proliferation, migration and metastasis of glioma cells. Oncol Lett. 2018;15:1475–82.
33. Mao XH, Chen M, Wang Y, Cui PG, Liu SB, Xu ZY. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4 and PTEN. Mol Carcinog. 2017;56:886–94.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more biomedcentral.com/submissions